Most actionable first. Assess the next decision, not the size of the database.
877 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.
WATCH · SUSPENDED
Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other,...
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT insufficient funding
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
insufficient funding
Why stranded: Financing failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-10. Registry source
WATCH · TERMINATED
ANCA Associated Systemic Vasculitis Including Wegener's, Granulomatosis and Microscopic Polyangiitis and, Renal Limited Vasculitis
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2006-04-10. Registry source
WATCH · TERMINATED
Immunosuppressive Agents, Kidney Failure, Chronic, Kidney Transplantation
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2005-09-20. Registry source
WATCH · TERMINATED
Kidney Transplantation
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-11-20. Registry source
WATCH · SUSPENDED
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Revisions to eligibility/design being made prior to enrollment of first participants.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Revisions to eligibility/design being made prior to enrollment of first participants.
Why stranded: Recruitment/execution failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-18. Registry source
WATCH · TERMINATED
Metastatic Non-Small Cell Lung Cancer
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated.
Why stranded: Endpoint failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-11. Registry source
WATCH · TERMINATED
Triple Negative Breast Neoplasms
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected...
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.
Why stranded: Corporate/strategic failure / Recruitment/execution failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-10. Registry source
WATCH · SUSPENDED
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic...
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Drug Supply Issues
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Drug Supply Issues
Why stranded: CMC/manufacturing failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-09. Registry source
WATCH · TERMINATED
Cancer, Venous Thromboembolism
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2006-03-16. Registry source
WATCH · WITHDRAWN
Hyperplasia
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-09. Registry source
WATCH · TERMINATED
Healthy
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Study never initiated.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Study never initiated.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-10-11. Registry source
WATCH · TERMINATED
Diabetes, Myocardial Infarction, Cardiovascular Disease
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT interim analysis showed significant differences between two treatment groups
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
interim analysis showed significant differences between two treatment groups
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-03-01. Registry source